PF-06651600 for the Treatment of Alopecia Areata
Public ClinicalTrials.gov record NCT03732807. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.
Study identification
- NCT ID
- NCT03732807
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 718 participants
Conditions and interventions
Conditions
Interventions
- PF-06651600 Induction Dose Drug
- PF-06651600 Maintenance Dose #1 Drug
- PF-06651600 Maintenance Dose #2 Drug
- PF-06651600 Maintenance Dose #3 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 3, 2018 (Actual)
- Primary completion
- Dec 31, 2020 (Actual)
- Completion
- Jun 24, 2021 (Actual)
- Last update posted
- Feb 24, 2022
2018 – 2021
United States locations
- U.S. sites
- 46
- U.S. states
- 20
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Alabama at Birmingham Hospital Outreach Lab | Birmingham | Alabama | 35233 | — |
| The University of Alabama at Birmingham, Department of Dermatology | Birmingham | Alabama | 35233 | — |
| The University of Alabama at Birmingham, Department of Dermatology | Birmingham | Alabama | 35294 | — |
| Mosaic Dermatology | Beverly Hills | California | 90211 | — |
| University of California, Irvine, Department of Dermatology, Dermatology Clinical Research Center | Irvine | California | 92697 | — |
| Dermatology Specialists, Inc. | Murrieta | California | 92562 | — |
| University of California, San Francisco | San Francisco | California | 94115 | — |
| Kaiser Permanente Clinical Trials Unit | San Francisco | California | 94118 | — |
| Southern California Dermatology, Inc. | Santa Ana | California | 92701 | — |
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital Clinical and Translational Research Center | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital Outpatient Pavillion | Aurora | Colorado | 80045 | — |
| Yale School of Medicine | New Haven | Connecticut | 06510 | — |
| Church Street Research Unit | New Haven | Connecticut | 06519 | — |
| Medstar Georgetown University Hospital Center-Department of Otolaryngology | Washington D.C. | District of Columbia | 20007 | — |
| Medstar Washington Hospital Center-Claude Nogay Research Pharmacy | Washington D.C. | District of Columbia | 20010 | — |
| Medstar Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | — |
| Medstar Georgetown University Hospital Center-Department of Pediatrics | Washington D.C. | District of Columbia | 20016 | — |
| Siperstein Dermatology Group | Boynton Beach | Florida | 33472 | — |
| Park Avenue Dermatology | Orange Park | Florida | 32073 | — |
| ForCare Clinical Research | Tampa | Florida | 33613 | — |
| Advanced Clinical Research | Meridian | Idaho | 83642 | — |
| Northwestern Medical Group | Chicago | Illinois | 60611 | — |
| Northwestern Medicine Diagnostic Testing Center | Chicago | Illinois | 60611 | — |
| Northwestern Medicine | Chicago | Illinois | 60611 | — |
| Northwestern Memorial Hospital, Investigational Research Pharmacy | Chicago | Illinois | 60611 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| NorthShore University HealthSystem | Skokie | Illinois | 60077 | — |
| Southern Illinois University School of Medicine | Springfield | Illinois | 62702 | — |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana | 46250 | — |
| University of Iowa Hospitals and Clinics; Department of Pharmacy-IDS; | Iowa City | Iowa | 52242 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Medstar Georgetown University Hospital - Department of Dermatology | Chevy Chase | Maryland | 20815 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| University of Minnesota Department of Dermatology | Minneapolis | Minnesota | 55455 | — |
| University of Minnesota Medical Center, Investigational Drug Services Attn: Darlette Luke | Minneapolis | Minnesota | 55455 | — |
| Skin Specialists, PC | Omaha | Nebraska | 68144 | — |
| The Dermatology Group, P.C. | Verona | New Jersey | 07044 | — |
| NYU School of Medicine, The Ronald O. Perelman Department of Dermatology | New York | New York | 10016 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| UNC CTRC | Chapel Hill | North Carolina | 27514 | — |
| UNC Hospitals, Investigational Drug Service | Chapel Hill | North Carolina | 27514 | — |
| UNC Dermatology Clinical Trials Unit | Chapel Hill | North Carolina | 27516 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Vital Prospects Clinical Research Institute, P.C | Tulsa | Oklahoma | 74136 | — |
| The University of Texas Health Science Center at Houston | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 109 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03732807, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03732807 live on ClinicalTrials.gov.